LivingGLP1
crossover randomized trial

NCT00099619

Efficacy of Exenatide Compared With Insulin Glargine in Patients With Type 2 Diabetes Using Metformin or Sulfonylurea for Whom Insulin is the Next Appropriate Therapy

Type 2 diabetes (adults)NCT00099619S002376

Design

Randomized
138
Start year
2004
Treatment
32 weeks
Countries
Sponsor
AstraZeneca (industry)
Eligibility
type 2 diabetes on metformin or sulfonylurea needing insulin

Conduct and analysis

Blinding
open label
Sequence generation
not reported
Allocation concealment
not reported
Outcome adjudication
not reported
Primary estimand
not stated
Analysis population
Missing data

Arms

ArmTreatmentBackgroundRandomizedAnalyzedCompleted treatment
A1Exenatide 10 ug subcutaneous twice daily
Exenatide 10 ug BID
metformin or sulfonylurea; lifestyle: not reported136
A2Insulin glargine
Insulin glargine titrated
metformin or sulfonylurea; lifestyle: not reported127